Medical oncology and tumor pharmacotherapy最新文献_第5页

Structural alterations of the ribosomal RNA genes in leukemic cells. 白血病细胞核糖体RNA基因的结构改变。

Medical oncology and tumor pharmacotherapy Pub Date : 1992-01-01 DOI: 10.1007/BF02987758

I A Smirnova

引用次数: 1

Weekly 5-fluorouracil and folinic acid plus escalating doses of cisplatin with glutathione protection in patients with advanced head and neck cancer. 晚期头颈癌患者每周5-氟尿嘧啶和亚叶酸加剂量递增的顺铂和谷胱甘肽保护

Medical oncology and tumor pharmacotherapy Pub Date : 1992-01-01 DOI: 10.1007/BF02987751

V Gebbia, R Valenza, A Testa, G Zerillo, S Restivo, G Cupido, F Ingria, G Spadafora, C Barbaccia, G Cannata

{"title":"Weekly 5-fluorouracil and folinic acid plus escalating doses of cisplatin with glutathione protection in patients with advanced head and neck cancer.","authors":"V Gebbia, R Valenza, A Testa, G Zerillo, S Restivo, G Cupido, F Ingria, G Spadafora, C Barbaccia, G Cannata","doi":"10.1007/BF02987751","DOIUrl":"https://doi.org/10.1007/BF02987751","url":null,"abstract":"Twenty-two patients with advanced head and neck carcinoma were treated with 5FU 400 mg-2 m-1 week and folinic acid 500 mg m-2 week-1 plus CDDP in escalating doses from 20 to 40 mg m-2 week-1 without forced diuresis. Reduced glutathione at the dose of 1.5 g m-2 was employed to protect patients from CDDP-related nephrotoxicity. The aims of the study were: a) to evaluate the therapeutic efficacy of this schedule, and b) to evaluate reduced glutathione as uroprotector. Out of 20 evaluable patients 14 (70%) had a major objective response. A CR with a mean duration of 9.0+ months was achieved in 15% of the patients, a PR of 5.8+ months in 55% of the patients, while 3 patients had stable disease and 4 progressed. It was possible to escalate CDDP up to 35 mg m-2 week-1, but at the dose of CDDP 40 mg m-2 week-1 the occurrence of grade 2 renal toxicity provoked a severe reduction of dose-intensity. Overall, this treatment has been very well tolerated by most patients with few cases of grade 3 gastrointestinal or hematological toxicity. In conclusion, the schedule seems effective and may be safely given to patients with advanced head and neck cancer on outpatient basis. Reduced glutathione seems to be able to reduce, at least partially, CDDP-related nephrotoxicity permitting the delivery of higher CDDP doses.","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"9 4","pages":"165-8"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02987751","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12514708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Cytosine arabinoside and etoposide (CARE) in relapsed and refractory non-Hodgkin's lymphoma. 阿糖胞嘧啶和依托泊苷(CARE)在复发和难治性非霍奇金淋巴瘤中的应用。

Medical oncology and tumor pharmacotherapy Pub Date : 1992-01-01 DOI: 10.1007/BF02987753

R Mansberg, J Gibson, D E Joshua, H Kronenberg

{"title":"Cytosine arabinoside and etoposide (CARE) in relapsed and refractory non-Hodgkin's lymphoma.","authors":"R Mansberg, J Gibson, D E Joshua, H Kronenberg","doi":"10.1007/BF02987753","DOIUrl":"https://doi.org/10.1007/BF02987753","url":null,"abstract":"Twelve patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) were treated with a 5 day protocol of high dose cytosine arabinoside 3 g/m2 and etoposide 200 mg/m2 (CARE) daily for 4 days for either 1 or 2 cycles together with alternating intrathecal cytosine arabinoside and methotrexate. Seven men and 5 women aged 18 to 65 years (median age 47.5 years) have received a total of 19 cycles. Six patients had Stage III and 6 had Stage IV disease, all with marrow involvement. Three patients had diffuse small lymphocytic NHL, 3 had diffuse large cell NHL, 3 had diffuse small cleaved NHL and 3 remaining patients had diffuse mixed small and large cell NHL, lymphoblastic NHL and Burkitt's. Six patients (50%) achieved complete remission (3-44 months), four of whom subsequently underwent successful autologous bone marrow transplantation and a fifth has had marrow harvested in preparation for ABMT. One patient achieved partial remission and 5 patients had no response to CARE. Ten patients had nadir granulocyte counts less than 0.5 x 10(9)/l and all required red cell (range 2-11 units) and platelet (range 6-130 units) transfusions. The platelet nadir was less than 20 x 10(9)/l in all patients. One patient with refractory disease succumbed to pulmonary haemorrhage while three other patients developed reversible toxicity with serve mucositis, prolonged diarrhoea and acute renal failure. One patient with refractory disease died with a progressive neuropathy.","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"9 4","pages":"173-6"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02987753","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12514711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epirubicin as a single agent therapy for the treatment of breast cancer--a pharmacokinetic and clinical study. 表柔比星单药治疗乳腺癌的药代动力学及临床研究。

Medical oncology and tumor pharmacotherapy Pub Date : 1992-01-01 DOI: 10.1007/BF02989657

S Eksborg, L Hardell, N O Bengtsson, M Sjödin, B Elfsson

{"title":"Epirubicin as a single agent therapy for the treatment of breast cancer--a pharmacokinetic and clinical study.","authors":"S Eksborg, L Hardell, N O Bengtsson, M Sjödin, B Elfsson","doi":"10.1007/BF02989657","DOIUrl":"https://doi.org/10.1007/BF02989657","url":null,"abstract":"Sixty women with breast cancer (mean age: 61 years; range 36-78 years) were treated with Epirubicin (4'epi-Doxorubicin), 60 mg m-2, as single drug therapy. The drug was administered as 2 hours' constant rate infusions. The pharmacokinetics of the drug during the first course of treatment was evaluated by measurements of the plasma concentration of Epirubicin at the end of the infusion period. There was a five-fold inter-individual variation of the dose-normalized maximum plasma concentration, which increased with increasing age of the patients. There was no correlation between this pharmacokinetic parameter and degree of obesity. An increase in maximum plasma concentration was associated with an increasing degree of alopecia (p = 0.025). Also the degree of nausea and vomiting showed a tendency to increase with increasing maximum plasma concentration (p = 0.07). Fifty four of the sixty patients entered in the present study were evaluable for clinical response. There was one CR (complete remission). Seventeen patients achieved PR (partial response), and twenty five patients had SD (stable disease). Eleven patients did not respond to treatment. The median maximum plasma concentrations were 322, 316, 336 and 288 ng ml-1 in patients with CR, PR, SD and PD, respectively. The results in the present study showed that 60 mg m-2 of Epirubicin given as a constant rate infusion over 2 hours is a useful alternative to more aggressive combination drug therapy for the treatment of breast cancer.","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"9 2","pages":"75-80"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02989657","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12515440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

Control of cisplatin induced emesis--a multidisciplinary intervention strategy. 控制顺铂致呕吐——多学科干预策略。

Medical oncology and tumor pharmacotherapy Pub Date : 1992-01-01 DOI: 10.1007/BF02989658

C J Fürst, S Johansson, M Fredrikson, T Hursti, G Steineck, C Peterson

引用次数: 6

Clinical management of prolactinomas: a ten-year experience. 泌乳素瘤的临床治疗:十年经验。

Medical oncology and tumor pharmacotherapy Pub Date : 1992-01-01 DOI: 10.1007/BF02989660

B Merola, A Colao, N Panza, E Caruso, R Spaziante, G Schettini, E de Divitiis, G Pacilio, G Lombardi

{"title":"Clinical management of prolactinomas: a ten-year experience.","authors":"B Merola, A Colao, N Panza, E Caruso, R Spaziante, G Schettini, E de Divitiis, G Pacilio, G Lombardi","doi":"10.1007/BF02989660","DOIUrl":"https://doi.org/10.1007/BF02989660","url":null,"abstract":"A ten-year experience on 36 patients bearing macroprolactinomas (MP) and 86 others bearing microprolactinomas (mP) is reported in this study. Different therapeutical approaches were used: 1) trans-sphenoidal surgery in 24 patients with MP and in 25 with mP; 2) medical therapy with the oral form of bromocriptine (BRC) in all the 24 patients with MP previously subjected to surgery, in 48 patients with mP ab initio, and in 16 out of 25 patients with mP previously subjected to surgery; 3) medical therapy with the long-acting injectable forms of BRC in 12 MP- and 13 mP-bearing patients, and 4) conventional radiotherapy in 12 of the 24 patients with MP previously subjected to surgery. The follow-up, performed five years after surgery, showed that: a) all the 24 patients with MP but one had normal PRL levels during BRC administration, with a rebound of hyperprolactinemia in all cases after withdrawal; b) during the treatment BRC caused normalization of PRL in 15 of the 16 mP-bearing patients surgically treated and in all the 48 mP-bearing patients only treated with BRC; c) in 20 of the 25 patients the treatment with injectable retard BRC caused the normalization of plasma PRL and the shrinkage of the tumor mass in all the patients with MP but one, as revealed by seriate CT scans. In conclusion, the surgical treatment of prolactinomas was ineffective to normalize plasma PRL levels in most patients whereas BRC, in standard or in retard forms, was able to normalize plasma PRL levels, reduce the tumoral mass and preserve the pituitary residual tissue. BRC should be, therefore, used as first choice therapy both for MP and mP.","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"9 2","pages":"93-9"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02989660","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12514655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

The incidence of HPV in a Swedish series of invasive cervical carcinoma. 瑞典一系列侵袭性宫颈癌中HPV的发病率。

Medical oncology and tumor pharmacotherapy Pub Date : 1992-01-01 DOI: 10.1007/BF02987743

B Hagmar, B Johansson, M Kalantari, Z Petersson, B Skyldberg, L Walaas

引用次数: 29

Serum soluble CD4, CD8 and IL-2R levels in adult acute myeloid leukemia in remission. 成人急性髓性白血病缓解期血清可溶性CD4、CD8和IL-2R水平。

Medical oncology and tumor pharmacotherapy Pub Date : 1992-01-01 DOI: 10.1007/BF02989655

Y Iizuka, M Aiso, T Ohshima, S Sawada, T Horie

引用次数: 2

In vitro analysis of drug resistance in tumor cells from patients with acute myelocytic leukemia. 急性髓细胞白血病患者肿瘤细胞体外耐药分析。

Medical oncology and tumor pharmacotherapy Pub Date : 1992-01-01 DOI: 10.1007/BF02989656

J Kristensen, B Jonsson, C Sundström, P Nygren, R Larsson

{"title":"In vitro analysis of drug resistance in tumor cells from patients with acute myelocytic leukemia.","authors":"J Kristensen, B Jonsson, C Sundström, P Nygren, R Larsson","doi":"10.1007/BF02989656","DOIUrl":"https://doi.org/10.1007/BF02989656","url":null,"abstract":"A 72 hours fluorometric microculture cytotoxicity assay (FMCA) was used for the study of chemotherapeutic drug resistance in tumor cell suspensions from patients with acute myelocytic leukemia (AML). A marked heterogeneity with respect to sensitivity was observed for a panel of cytotoxic drugs tested in 76 samples from 60 patients with treated or untreated AML. Primary resistance to vincristine (Vcr) and prednisolone in untreated AML was observed as well as 'acquired' resistance to several other antileukemic drugs. Cross resistance patterns for AML active drugs revealed significant positive relationships between anthracyclines, VP16 and amsacrine (Amsa), whereas mitoxantrone (Mitox) was more weakly correlated. Sensitivity to cytosine arabinoside was unrelated to the anthracyclines, VP16, Amsa and Mitox but showed a significant relationship to 6-thioguanine. Several resistance modifying agents, including the novel non-immunosuppressive cyclosporin A analogue PSC 833, were able to potentiate the effects of doxorubicin and Vcr at concentrations achievable in the clinic. However, the pattern of activity was heterogenous and the frequency of responsive samples was higher in relapse compared to de novo cases. Individual in vitro/in vivo correlations based on quartile distributions of all accumulated drug sensitivity data from AML patients indicated a high specificity with respect to the identification of drug resistance. The results suggest that the FMCA may provide clinically valuable information on chemotherapeutic drug resistance in AML.","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"9 2","pages":"65-74"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02989656","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12515439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

The multiple drug resistance gene, MDR1: expression at the protein and RNA levels. 多重耐药基因MDR1:在蛋白和RNA水平表达。

Medical oncology and tumor pharmacotherapy Pub Date : 1992-01-01 DOI: 10.1007/BF02989647

Y Q Li, V Gopal, P Kadam, S Files, H Preisler

引用次数: 2